Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication May 31, 2016
- Accepted for publication August 1, 2016
- Published online February 1, 2017.
Article Versions
- previous version (September 15, 2016 - 05:45).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Stephanie Robu*,1,
- Margret Schottelius*,1,
- Matthias Eiber2,
- Tobias Maurer3,
- Jürgen Gschwend3,
- Markus Schwaiger2 and
- Hans-Jürgen Wester1
- 1Chair of Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany
- 2Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, München, Germany; and
- 3Department of Urology, Klinikum Rechts der Isar, Technische Universität München, München, Germany
- For correspondence or reprints contact: Stephanie Robu, Chair for Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meissner-Strasse 3, 85748 Garching, Germany. E-mail: stephanie.robu{at}tum.de
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- A New Labelling Method of 99mTc-PSMA-HBED-CC
- Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of 99mTc and 188Re Theranostic Agents for Prostate Cancer
- Strong Correlation Between SUVmax on PSMA PET/CT and Numeric Drop-In {gamma}-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions
- Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial
- Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer
- A 2022 International Survey on the Status of Prostate Cancer Theranostics
- Occupational Radiation Exposure of Radiopharmacy, Nuclear Medicine, and Surgical Personnel During Use of [99mTc]Tc-PSMA-I&S for Prostate Cancer Surgery
- Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study
- Can Intraoperative Fluorescence Imaging Identify All Lesions While the Road Map Created by Preoperative Nuclear Imaging Is Masked?
- Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction
- Prostate-Specific Membrane Antigen-Guided Surgery
- Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer
- Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
- PSMA Ligands for PET Imaging of Prostate Cancer
- Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers